GlassScriptPhysician profile
Tyler Arendt
NPI 1912430950
$6,081.35
in general payments reported to CMS, 2019-2025
26 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $158 · 2021: $623 · 2022: $1,044 · 2023: $1,344 · 2024: $1,483 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,237 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,236.76 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $790.39 | 2020-2025 | |
| Novo Nordisk INC | $774.80 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $659.96 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $658.22 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $649.35 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $593.48 | 2021-2025 | |
| Glaxosmithkline, LLC. | $403.82 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.89 | 2021-2025 | Jardiance |
| Amgen INC. | $191.78 | 2022-2024 | Otezla, Repatha, Evenity |
| Exact Sciences Corporation | $172.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $131.90 | 2020-2023 | Yupelri |
| Astellas Pharma US INC | $113.99 | 2022-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $105.20 | 2024-2025 | Voquezna |
| Alkermes, INC. | $104.57 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.83 | 2021-2024 | Xifaxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $60.84 | 2022 | |
| Idorsia Pharmaceuticals US INC | $56.43 | 2022-2023 | Quviviq |
| Inspire Medical Systems, INC. | $22.16 | 2025 | Inspire |
| Abbott Laboratories | $21.91 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.86 | 2023 | |
| Biogen, INC. | $20.41 | 2021 | |
| Genentech USA, INC. | $18.62 | 2021 | |
| Merck Sharp & Dohme LLC | $18.34 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.20 | 2024 | Nuzyra |
| Orthofix Medical, INC. | $12.23 | 2025 | Physio-Stim |
| Allergan, INC. | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Arendt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.